Drug Trial Radar · NCT06157450
Pharmacokinetics of ZSP1273 in Elder Participants
Last checked: Nov 19, 2026Latest source record: Dec 5, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
32
Actual
Start
Oct 11, 2023
Primary completion
Nov 1, 2023
Study completion Nov 17, 2023
Sponsor
- Lead sponsor
- Guangdong Raynovent Biotech Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Dec 5, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety, tolerability and PK of ZSP1273 in elder Participants
Conditions
- Elder
Interventions
ZSP1273Drug
Participants receive ZSP1273 orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum observed plasma concentration (Cmax)Time frame: Day 1 to Day 5
- Area under the concentration-time curve from time zero to infinity (AUCinf)Time frame: Day 1 to Day 5
- Area under the concentration-time curve from time zero to last time of quantifiable concentration (AUClast)Time frame: Day 1 to Day 5
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sir Run Run Hospital
Nanjing, Jiangsu, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.